Skip to main content

Table 1 Characteristics of the PLWH (n = 138) and HNCs (n = 35) in Wuhan, China, 2021

From: Humoral immune response to inactivated COVID-19 vaccination at the 3rd month among people living with HIV

Characteristics

PLWH (n = 138)

HNCs (n = 35)

Statistics

P

Age in years, median (IQR)

38 (31–49)

33 (29–44)

2.56

0.08

Men, No. (%)

16 (88.4)

17 (48.6)

28.06

< 0.001

Comorbidities (%)

17 (12.3)

2 (5.7)

0.26

CD4 cell count/μL, median (IQR)

495 (320–646)

666 (534–800)

4.12

< 0.001

CD4 cell count (/μL)

    

 < 200

18

0

  

 200–500

52

4

  

 ≥ 500

68

31

18.04

< 0.001

Receiving ART, n (%)

126 (91.3)

  

ART regimens

    

No

12 (8.7)

  

NNRTIs (NVP/EFV)

102 (73.9)

  

INSTIs (EVG/DTG)

14 (10.1)

  

PIs (LPV/r)

10 (7.3)

  

HIV VL < 50 copies/mL

107 (77.5)

   

IgM, n (%)

5 (3.6)

1 (2.9)

–*

1.00

IgG,n (%)

62 (44.9)

21 (60.0)

 

0.11

nAbs,n (%)

40 (29.0)

17 (48.6)

4.85

0.03

IgM titers, GMT (95% CI)

0.016 (0.014–0.020)

0.018 (0.013–0.024)

1.18

0.24

IgG titers, GMT (95% CI)

0.10 (0.074–0.13)

0.21 (0.14–0.32)

1.97

0.049

Log10 nAbs titers, median (IQR)

0.57 (0.30–1.11)

0.91 (0.64–1.26)

2.46

0.01

  1. NNRTIs: nonnucleoside reverse transcriptase inhibitors; INSTIs: integrase inhibitors; PIs: protein inhibitors; NVP: nevirapine; EFV: efavirenz; EVG: elvitegravir; DTG: dolutegravir; LPV/r: lopinavir/ritonavir
  2. *No statistics are computed because Fisher exact method was used